Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Cipla
Deloitte
Chubb
Medtronic
Farmers Insurance
Argus Health
McKesson
US Army

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022160

« Back to Dashboard

NDA 022160 describes OXALIPLATIN, which is a drug marketed by Accord Hlthcare, Actavis Totowa, Cipla Ltd, Fresenius Kabi Oncol, Fresenius Kabi Usa, Gland Pharma Ltd, Hospira Inc, Hospira Worldwide, Jiangsu Hengrui Med, Luitpold Pharms Inc, Mylan Labs Ltd, Qilu Pharm Co Ltd, Sandoz, Sandoz Inc, Sanja Pharms Co, Sun Pharma Global, and Teva Pharms, and is included in twenty-four NDAs. It is available from nineteen suppliers. Additional details are available on the OXALIPLATIN profile page.

The generic ingredient in OXALIPLATIN is oxaliplatin. There are twenty-six drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the oxaliplatin profile page.
Summary for 022160
Tradename:OXALIPLATIN
Applicant:Teva Pharms
Ingredient:oxaliplatin
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 022160
Suppliers and Packaging for NDA: 022160
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
OXALIPLATIN oxaliplatin INJECTABLE;IV (INFUSION) 022160 NDA Teva Parenteral Medicines, Inc. 0703-3985 0703-3985-01 1 VIAL, SINGLE-USE in 1 CARTON (0703-3985-01) > 10 mL in 1 VIAL, SINGLE-USE
OXALIPLATIN oxaliplatin INJECTABLE;IV (INFUSION) 022160 NDA Teva Parenteral Medicines, Inc. 0703-3986 0703-3986-01 1 VIAL, SINGLE-USE in 1 CARTON (0703-3986-01) > 20 mL in 1 VIAL, SINGLE-USE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;IV (INFUSION)Strength50MG/10ML (5MG/ML)
Approval Date:Aug 7, 2009TE:APRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;IV (INFUSION)Strength100MG/20ML (5MG/ML)
Approval Date:Aug 7, 2009TE:APRLD:Yes

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Harvard Business School
Argus Health
Daiichi Sankyo
Farmers Insurance
QuintilesIMS
Baxter
Cipla
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot